

Paul N Mortenson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4111367/publications.pdf>

Version: 2024-02-01

30
papers

2,106
citations

331259

21
h-index

433756

31
g-index

32
all docs

32
docs citations

32
times ranked

2879
citing authors

#	ARTICLE	IF	CITATIONS
1	ParaMol: A Package for Automatic Parameterization of Molecular Mechanics Force Fields. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 2026-2047.	2.5	22
2	A knowledge-based, structural-aided discovery of a novel class of 2-phenylimidazo[1,2-a]pyridine-6-carboxamide H-PGDS inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 47, 128113.	1.0	3
3	C ¹³ H functionalisation tolerant to polar groups could transform fragment-based drug discovery (FBDD). <i>Chemical Science</i> , 2021, 12, 11976-11985.	3.7	30
4	Generation of Quantum Configurational Ensembles Using Approximate Potentials. <i>Journal of Chemical Theory and Computation</i> , 2021, 17, 7021-7042.	2.3	2
5	Fragment-to-Lead Medicinal Chemistry Publications in 2018. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4430-4444.	2.9	61
6	The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115791.	1.4	4
7	Fragment-to-Lead Medicinal Chemistry Publications in 2019. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15494-15507.	2.9	41
8	Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4683-4702.	2.9	59
9	The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1456-1478.	1.4	17
10	Fragment-to-Lead Medicinal Chemistry Publications in 2017. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3857-3872.	2.9	47
11	Fragment-to-Lead Medicinal Chemistry Publications in 2016. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1774-1784.	2.9	41
12	Predicting Hot and Warm Spots for Fragment Binding. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4036-4046.	2.9	32
13	Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 798-803.	1.3	49
14	Allosteric Inhibition of the Neuropeptidase Neurolysin. <i>Journal of Biological Chemistry</i> , 2014, 289, 35605-35619.	1.6	18
15	Efficient exploration of chemical space by fragment-based screening. <i>Progress in Biophysics and Molecular Biology</i> , 2014, 116, 82-91.	1.4	127
16	Fragment-Based Approaches to the Discovery of Kinase Inhibitors. <i>Methods in Enzymology</i> , 2014, 548, 69-92.	0.4	13
17	Identification of orally bioavailable small-molecule inhibitors of hematopoietic prostaglandin D2 synthase using X-ray fragment based drug discovery. <i>MedChemComm</i> , 2014, 5, 134-141.	3.5	8
18	Fragment-Based Discovery of 6-Azaindazoles As Inhibitors of Bacterial DNA Ligase. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1208-1212.	1.3	21

#	ARTICLE	IF	CITATIONS
19	Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 445-449.	1.3	34
20	Docking Performance of Fragments and Druglike Compounds. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5422-5431.	2.9	109
21	Assessing the lipophilicity of fragments and early hits. <i>Journal of Computer-Aided Molecular Design</i> , 2011, 25, 663-667.	1.3	95
22	Discovery of 2-(6-((6-Fluoroquinolin-2-yl)methyl)amino)bicyclo[3.1.0]hex-3-yl)- <i>N</i> -hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 8663-8678.	2.9	74
23	DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 894-899.	1.0	70
24	Discovery of novel inhibitors of <i>Trypanosoma cruzi</i> trans-sialidase from in silico screening. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 589-596.	1.0	68
25	Protein-Ligand Docking against Non-Native Protein Conformers. <i>Journal of Chemical Information and Modeling</i> , 2008, 48, 2214-2225.	2.5	129
26	Energy Landscapes: From Clusters to Biomolecules. <i>Advances in Chemical Physics</i> , 2007, , 1-111.	0.3	153
27	Diverse, High-Quality Test Set for the Validation of Protein-Ligand Docking Performance. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 726-741.	2.9	546
28	Energy landscapes of model polyanilines. <i>Journal of Chemical Physics</i> , 2002, 117, 1363-1376.	1.2	78
29	Energy landscapes, global optimization and dynamics of the polyaniline Ac(ala) ₈ NHMe. <i>Journal of Chemical Physics</i> , 2001, 114, 6443-6454.	1.2	77
30	Crystals of binary Lennard-Jones solids. <i>Physical Review B</i> , 2001, 64, .	1.1	77